H
Hannah M. Jacobs
Researcher at Harvard University
Publications - 4
Citations - 2779
Hannah M. Jacobs is an academic researcher from Harvard University. The author has contributed to research in topics: Bromodomain & Coactivator. The author has an hindex of 3, co-authored 4 publications receiving 2324 citations.
Papers
More filters
Journal ArticleDOI
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore,Ghayas C Issa,Madeleine E. Lemieux,Peter B. Rahl,Junwei Shi,Hannah M. Jacobs,Efstathios Kastritis,Timothy Gilpatrick,Ronald M. Paranal,Jun Qi,Marta Chesi,Anna C. Schinzel,Michael R. McKeown,Timothy P. Heffernan,Christopher R. Vakoc,P. Leif Bergsagel,Irene M. Ghobrial,Paul G. Richardson,Richard A. Young,William C. Hahn,William C. Hahn,Kenneth C. Anderson,Andrew L. Kung,James E. Bradner,Constantine S. Mitsiades +24 more
TL;DR: In this paper, a small-molecule bromodomain inhibitor, JQ1, was used to identify BET proteins as regulatory factors for c-Myc oncoprotein.
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore,Ghayas C Issa,Madeleine E. Lemieux,Peter B. Rahl,Junwei Shi,Hannah M. Jacobs,Efstathios Kastritis,Timothy Gilpatrick,Ronald M. Paranal,Jun Qi,Marta Chesi,Anna C. Schinzel,Michael R. McKeown,Timothy P. Heffernan,Christopher R. Vakoc,P. Leif Bergsagel,Irene M. Ghobrial,Paul G. Richardson,Richard A. Young,William C. Hahn,William C. Hahn,Kenneth C. Anderson,Andrew L. Kung,James E. Bradner,Constantine S. Mitsiades +24 more
TL;DR: Efficacy of JQ1 in three murine models of multiple myeloma establishes the therapeutic rationale for BET bromodomain inhibition in this disease and other malignancies characterized by pathologic activation of c-Myc.
Journal ArticleDOI
Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma
Douglas W. McMillin,Hannah M. Jacobs,Jake Delmore,Leutz Buon,Zachary R. Hunter,Val Monrose,Jie Yu,Peter G. Smith,Paul G. Richardson,Kenneth C. Anderson,Steven P. Treon,Andrew L. Kung,Constantine S. Mitsiades +12 more
TL;DR: The NEDD8-activating enzyme is upstream of the 20S proteasome in the ubiquitin/proteasome pathway and catalyzes the first step in the neddylation pathway and provides the framework for the clinical investigation of MLN4924 in multiple myeloma.
Journal ArticleDOI
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
Douglas W. McMillin,Jake Delmore,Joseph Negri,Leutz Buon,Hannah M. Jacobs,Jacob P. Laubach,Jana Jakubikova,Melissa G. Ooi,Patrick Hayden,Robert L. Schlossman,Nikhil C. Munshi,Nikhil C. Munshi,Christoph Lengauer,Paul G. Richardson,Kenneth C. Anderson,Constantine S. Mitsiades +15 more
TL;DR: In this article, the small molecule heterocyclic compound NVP-LCQ195/AT9311 (LCQ 195) was used to induce cell cycle arrest and eventual apoptotic cell death of MM cells.